Common Genitourinary Symptoms in Midlife Women Flashcards
GSM
-collection of s/sxs a/w estro deficiency that lead to change in labia, introitus, vagina, clitoris, bladder, & urethra that must be bothersome to the woman & not caused by another dx
-VVA is a component of GSM
-chronic & progressive condition
-sxs are unlikely to improve wo tx
S/Sxs of GSM
-loss of elasticity
-shortening of vaginal vault
-narrowing of the introitus
-loss of vaginal rugae
-diminished blood flow
-thinning of vaginal tissue
-mucosal changes:
>petechiae, pallor, microfissures
>dryness
>irritation
>burning
>soreness
>tightness
>frequent/recurring UTIs
>lack of moisture w sexual activity
>dyspareunia
Evaluation of GSM
-complete med hx: sxs characterization, prior tx, review of vaginal irritants
-sexual hx
-PE: vaginal pH, wet prep as indicated, vulvar/vaginal cxs as appropriate, bx white, pigmented, or thickened lesions
-any vulvar lesion that does not response to tx should be bx’d
Prevalence of GSM
-more than 50M US women +52yo
-20-84% of meno women are affected by VVA
-about half of sexually active meno women experience bothersome sxs of GSM/VVA
-meno women w sexual dysfunction are 4x more likely to have VVA sxs
-most sxs are vaginal dryness & dyspareunia
-negatively affects sexual intimacy & QOL
Other Causes of GSM
-conditions resulting in low estrogen state:
>prolonged lactation, hypothalamic amenorrhea, POI, tx w gonadotropin-release hormone agonists/antagonists, ovarian surgery, chemotherapy, pelvic radiation, tx w aromatase inhibitors
Tx for GSM: Nonhormone therapies
-vulvovaginal moisturizers
-vulvovaginal lubricants
-PFPT
-vaginal dilators
-regular vulvovaginal stimulation
-penetrative sexual activity
-topical lidocaine
-fractional laser (not a lot of support)
Tx for GSM: Lubricants & Moisturizers
-Lubricants: water-based, silicone-based, oil-based
-moisturizers: last longer
Tx for GSM: Vaginal & Pelvic Floor Activity
-regular stimulation of the vulva & vagina promote blood flow to genital area & natural secretions help maintain vaginal health
-penetrative sexual activity w/wo partner may help maintain vaginal width, length, & tone
-severe GSM may require PFPT & vaginal dilators to treat provoked pelvic floor hypertonus in combo w pharmaco interventions to treat atrophic epithelial changes for optimal outcomes
Tx for GSM: Fractional CO2 Laser
-laser therapy helps w vaginal laxity & incontinence therapy - still controversial
-not FDA-approved for tx of GSM
-some studies show benefit of 3 treatments (6 wks apart)
-vaginal sxs & sexual function scores increased by 3mo, w some continued improvement at 1yr
-trials comparing laser vs vaginal ET still ongoing
-more studies needed d/t expensive technology & unknown long-term effects
Tx for GSM: HT
-for moderate to severe sxs & those who do not respond to lubricants/moisturizers
>low-dose vaginal ET
>vaginal DHEA
>ospemifene
>systemic ET (when VMS are also present)
HT: Low-dose Vaginal Estrogen
-restores vaginal blood flow, decr vaginal pH, improves thickness & elasticity of vulvovaginal tissues
-different forms: ring, tablets, creams
-improves w/in a few weeks, w full efficacy in 2-3 mo
-serum levels typically in postmeno range
-large study show no increased risk of endometrial ca, breast ca, CVD
-addition of progestogen not indicated
-obese women incr risk of endometrial ca, endometrial surveillance or intermittent progestogen w/drawal might be considered
-any vaginal bleeding should be evaluated
HT: DHEA
-dehydroepiandosterone
-0.5%/6.5mg DHEA vaginal suppository
-FDA approved for moderate to severe dyspareunia 2/2 VVA
-insert qD at HS
-phase 3 study showed significant improvement of: vaginal maturation index (VMI), vaginal pH, signs of atrophy, vaginal dryness, dyspareunia
-serum steroid levels remained w/in the normal postmeno range
-AE: vaginal discharge bc of melting suppository
-Safety: endometrial safety confirmed at 1y
HT: Ospemifene
-selective estrogen receptor modulator: estrogen agonist/antagonist
-FDA approved for moderate to severe dyspareunia a/w VVA
-daily oral admin (60mg)
-improves: VMI, vaginal pH, symptoms of VVA
-Safety: no endometrial hyperplasia or cancer (at 52 wks); can increase VMS, may incr risk of VTE
-antiestrogenic effects on breast but not approved for women w breast ca
-favorable effects on bone
Other Vulvar & Vaginal Sxs
-conditions other than GSM can cause vulvovaginal sxs in postmeno women
-vulvodynia - vulvar pain of at least 3mo duration wo identifiable cause (dx of exclusion & there are limited RCTs to guide tx)
-vulvovaginitis - caused by candida, BV, STIs, or desquamative inflammatory vaginitis
-dx of vaginitis is made of use pH, saline, KOH microscopy & testing for gonorrhea & chlamydia as indicated; tx is specific to infection
Vulvovaginal Conditions
-lichen sclerosus & lichen plan us are chronic inflammatory disease of the vulva that cause severe pruritis & pain
-appears as while plaques & papules or as erosive-appearing ulcerations, sometimes w fissuring
-dx’d by bx & tx is usually w high-potency topical steroid
-various forms of dermatitis, including contact & allergic are common & can be r/t soaps, detergents, other irritating; good vulvar hygiene & reducing irritants help relieve sxs
-lichen simplex chronicus, psoriasis, & seborrheic dermatitis also may affect the vulva